Biotechnology company Cereno Scientific (Nasdaq First North:CRNO B) announced on Friday that the first patient has been dosed with CS1 under its Expanded Access Program (EAP) for Pulmonary Arterial Hypertension (PAH).
This program allows patients who completed the Phase II trial to continue receiving CS1 based on perceived benefit, as determined by both the patient and physician.
The EAP aims to gather extensive data on long-term CS1 usage, supporting future regulatory discussions and pivotal trial planning. Approved since January 30, 2024, the EAP is an extension of the Phase II trial under an FDA protocol.
CS1, an HDAC inhibitor targeting PAH, has shown potential in Phase II trials, with topline results expected in Q3 2024.
FDA grants priority review to Innoviva's zoliflodacin for treatment of gonorrhea
AB Science secures Canadian patent for AB8939, completing global IP coverage for AML treatment
US FDA approves expanded indication for AbbVie's MAVYRET (glecaprevir/pibrentasvir) in acute HCV
Creo Medical secures FDA clearance for SpydrBlade Flex in US market
Psilera collaborates with Hesperos for PSIL-006 preclinical modelling for frontotemporal dementia
Myosin Therapeutics' MT-125 cleared by US FDA to initiate first-in-human trial in glioblastoma
Ondine's Steriwave proven effective against deadly Mucor fungus
AB Science receives EMA approval to extend Masivet shelf life to four years
Hemispherian's GLIX1 receives positive EU opinion for orphan designation in glioma
Arvinas and Pfizer submit FDA application for vepdegestrant in ESR1-mutated breast cancer
NRx Pharmaceuticals files ANDA for preservative-free IV ketamine
Innovent's IBI363 granted second breakthrough therapy designation in China
Implantica reports positive NICE guidance for RefluxStop procedure in UK hospitals